Capsugel: Micro-Dosing Tech Can Cut Drug Development by 6 Months

Loading the player...

Capsugel says its Xcelodose Precision Powder Micro-Dosing System can shorten drug development time by up to six months. spoke with Missy Lowery, Marketing Manager for the Americas at Capsugel, at this year’s Interphex in New York City about the company’s Fast track Solutions System and its Xcelodose proprietary technology.

“Speed to market is the most important” thing in the pharma market today, she told us.

“Capsugel’s proprietary technology provides an RSD of 1% for quantities as low as 100microgrammes directly into the capsule.”

She told us that Xcelodose was established in order for companies to put APIs directly in a capsule without going through the process of formulation first.

From concept to first clinical trial, Lowery said this technology has sped the whole process up by more than six months.

With “the accuracy of dosing, the continuation of the RSD,” she added, “there is nothing like it on the market right now.”

Related News

Capsugel Launches Lipidex Encapsulating Platform from New DFS Unit

Capsugel Launches Lipidex Encapsulating Platform from New Dosage Form Unit

Capsugel to Buy Bend Research to dosage solutions business

Capsugel to Buy Bend Research to Expand Bioavailability Offering

Capsugel and Bend begin tech transfer following takeover

Capsugel and Bend: 'Marriage made in heaven' as first tech transferred

Capsugel: 'More than a capsule maker,' as it wins manufacturing contract

'No longer simply a capsule provider' - Capsugel wins oral peptide contract

Capsugel is formulating biotherapeutics to be delivered into the lungs

Capsugel focusing on inhaled biotherapeutics from Bend facility

The Xceledose system: "similar to ‘tapping a pepper pot'" - photo Istock/AlonsoAguilar

'Drug-in-capsule' demand for trial material drives Juniper micro-dose investment

New DFS Unit Built on Technology, R&D and Manufacturing, says Capsugel

New DFS Unit Built on Technology, R&D and Manufacturing, says Capsugel

Capsugel expands liquid fill capsule capabilities

Capsugel Buys Encap Drug Delivery

Capsugel Buys Encap as Part of Dosage Form Solution Strategy

Capsugel announce new dosage form business unit

Capsugel Launches New Oral Formulation Business Unit

Pfizer to sell Capsugel for $2.4bn, no decision on other divestitures yet

Qualicaps expand oral dose manufacture: competition heats up

Oral Dose Competition Intensifies as Qualicaps Expands Manufacturing

Related Products

See more related products